Meet our new members

A warm welcome to our newest members! Oslo Cancer Cluster’s diverse member base includes university hospitals, research centres, patient organizations, start-ups, biotech and technology companies, global pharma, investors, financial institutions, and service providers.

Together, they cover the whole spectrum of oncology, contributing to a unique ecosystem that accelerates the development of innovative cancer treatments.

Oslo Cancer Cluster works tirelessly together with our members to enhance the development of novel cancer diagnostics and therapies to improve patients’ lives worldwide.

We are proud to announce that the following companies have recently joined our cluster:

ImmunoQuest Therapeutics

Elpis Biopharma

Aktiv mot kreft

This week, we engaged with the new members to gain insight into their decision to join our ecosystem and the key initiatives they are advancing.

ImmunoQuest Therapeutics

“We believe collaboration between biotech companies, academia, investors, and healthcare providers is essential for bringing groundbreaking therapies to patients," said Esmaeil Dorraji, CSO and founder, ImmunoQuest Therapeutics.

ImmunoQuest Therapeutics is a preclinical biopharmaceutical company specialising in precision oncology. They are developing targeted therapies known as Antibody-Drug Conjugates (ADCs) specific for p95HER2. This form of the HER2 protein is found only in tumours and is a key reason why cancer metastasises and becomes treatment-resistant to current HER2 therapies.

The company's lead drug, NAZ-001, is the first of its kind designed to target only the p95HER2 protein. This is important because about 80% of HER2-positive breast cancers have this protein, but existing drugs cannot fight it. This leaves patients with limited treatment options and poor outcomes. By focusing on this unique biomarker, ImmunoQuest is advancing a highly specific, tumour-selective, and potentially safer therapeutic approach.

This same target is also found in other major cancers like ovarian, lung, and colorectal cancer. This means the therapy has substantial potential and could one day benefit a large and diverse group of patients.

Elpis Biopharmaceuticals

Elpis Biopharmaceuticals is a clinical-stage cell therapy company based in Boston and Singapore, specialising in innovative technologies to treat solid tumours. The company’s therapies are currently in clinical trials in China, with interim results expected by the end of 2025.

As part of its global expansion, Elpis has joined Oslo Cancer Cluster to establish a European presence, collaborate with leading cancer researchers, and explore strategic partnerships and clinical trial opportunities across the continent.

“We are inspired by Norway’s growing leadership in advanced therapeutics and see this as a valuable opportunity to explore synergies in novel targets, manufacturing capabilities, and European clinical trial infrastructure,” said Chee Yong, co-founder & co-CEO.

Elpis is advancing a robust pipeline of first- and best-in-class treatments for cancers with high unmet needs, including glioblastoma, pancreatic, colorectal, lung, and bladder cancers. Its breakthrough technology enhances the immune system’s ability to attack solid tumours more effectively by targeting multiple tumor pathways at once and strengthening immune cells to last longer, without harmful side effects. Together, these innovations are paving the way for safer, more powerful, and longer-lasting cancer treatments.

Aktiv mot kreft

Aktiv mot kreft (AKTIV Against Cancer) is a foundation dedicated to ensuring that personalised physical exercise becomes a standard part of cancer treatment, starting from the time of diagnosis.

To achieve this goal, Aktiv mot kreft has opened small fitness centers called Pusterom (Norwegian for "breathing room") in 24 hospitals across Norway. Additionally, the foundation collaborates with the Norwegian School of Sport Sciences (NIH) and Oslo University Hospital to educate AKTIVinstructors.

“We’re moving our office into John Ugelstads Hus in the beginning of 2026, and are looking very much forward to becoming a part of the ecosystem at Campus Radiumhospitalet, and becoming a member of Oslo Cancer Cluster is a natural part of this,” said Helle Aanesen, General Manager in Aktiv mot kreft.